115 related articles for article (PubMed ID: 8773780)
1. Elevated striatal dopamine levels following administration of D-DOPA and its alpha-keto acid metabolite DHPPA: behavioral and physiological studies in vivo in the rat.
Brannan T; Prikhojan A; Yahr MD
Brain Res; 1996 Apr; 718(1-2):165-8. PubMed ID: 8773780
[TBL] [Abstract][Full Text] [Related]
2. Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
Brannan T; Prikhojan A; Yahr MD
Brain Res; 1998 Feb; 784(1-2):148-53. PubMed ID: 9518585
[TBL] [Abstract][Full Text] [Related]
3. D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in rats.
Karoum F; Freed WJ; Chuang LW; Cannon-Spoor E; Wyatt RJ; Costa E
Brain Res; 1988 Feb; 440(1):190-4. PubMed ID: 3129126
[TBL] [Abstract][Full Text] [Related]
4. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
5. The effect of simultaneous administration of 3,4-dihydroxyphenylpyruvic acid and L-dopa on the bioavailability of L-dopa in rat and mouse.
Hietala P; Lindén IB; Grönfors N
J Pharm Pharmacol; 1979 Apr; 31(4):205-8. PubMed ID: 36456
[TBL] [Abstract][Full Text] [Related]
6. Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal lesions.
Khan SM; Smith TS; Bennett JP
J Neurosci Res; 1999 Jan; 55(1):71-9. PubMed ID: 9890435
[TBL] [Abstract][Full Text] [Related]
7. High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats.
Lacombe E; Carcenac C; Boulet S; Feuerstein C; Bertrand A; Poupard A; Savasta M
Eur J Neurosci; 2007 Sep; 26(6):1670-80. PubMed ID: 17822436
[TBL] [Abstract][Full Text] [Related]
8. Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian rat.
Moses J; Siddiqui A; Silverman PB
Neurosci Lett; 1996 Nov; 218(3):145-8. PubMed ID: 8945749
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA.
Maeda T; Nagata K; Yoshida Y; Kannari K
Brain Res; 2005 Jun; 1046(1-2):230-3. PubMed ID: 15894297
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
11. Effects of 3,4-dihydroxyphenylpyruvic acid and L-glutamic acid on some pharmacokinetic parameters of L-dopa in the rat.
Lindén IB
J Pharm Pharmacol; 1980 May; 32(5):344-8. PubMed ID: 6104700
[TBL] [Abstract][Full Text] [Related]
12. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
Gołembiowska K; Dziubina A
Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
[TBL] [Abstract][Full Text] [Related]
13. Transamination and other metabolic pathways of 3,4-dihydroxyphenylpyruvic acid in rats when simultaneously administered with L-dopa.
Lindén IB; Karlsson M; Niemi S; Penttilä A
J Pharm Pharmacol; 1982 Nov; 34(11):719-23. PubMed ID: 6129302
[TBL] [Abstract][Full Text] [Related]
14. L-DOPA does not facilitate nitric oxide production in the rat striatum and substantia nigra: in vivo microdialysis study.
Kashihara K; Sakai K; Marui K; Shohmori T
Life Sci; 1998; 63(4):PL59-64. PubMed ID: 9698040
[TBL] [Abstract][Full Text] [Related]
15. An in vivo comparison of the capacity of striatal versus extrastriatal brain regions to form dopamine from exogenously administered L-dopa.
Brannan T; Prikhojan A; Yahr MD
J Neural Transm (Vienna); 1996; 103(11):1287-94. PubMed ID: 9013415
[TBL] [Abstract][Full Text] [Related]
16. L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation.
Pinheiro-Carrera M; Tomaz C; Huston JP; Dai H; Carey RJ
Life Sci; 1994; 55(13):991-7. PubMed ID: 8084215
[TBL] [Abstract][Full Text] [Related]
17. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
18. Effects of 3,4-dihydroxyphenylpyruvic acid and its triacetylated derivative on DOPA decarboxylase.
Lindén IB; Neuvonen PJ; Vapaatalo H
Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):266-9. PubMed ID: 7136732
[TBL] [Abstract][Full Text] [Related]
19. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
Nakazato T; Akiyama A
Brain Res; 2002 Mar; 930(1-2):134-42. PubMed ID: 11879803
[TBL] [Abstract][Full Text] [Related]
20. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
